{"links":{"html":"https://www.erudio.com/reports/optitrop-lung06-nct06711900","json":"https://www.erudio.com/reports/optitrop-lung06-nct06711900.json","markdown":"https://www.erudio.com/reports/optitrop-lung06-nct06711900.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"optitrop-lung06-06711900"}},"request":"https://www.erudio.com/contact?report=optitrop-lung06-06711900"},"offer":{"cited_commentary_sources":8,"verified_hcp_statements":13,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":7,"optional":true,"price_per_verified_person_usd":15,"price_usd":105,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"optitrop-lung06-nct06711900"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=optitrop-lung06-06711900","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/optitrop-lung06-nct06711900","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T08:44:01.797003Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":0},"aspects":[{"claim_count":7,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":7,"title":"Primary endpoint: Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)"},{"claim_count":8,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":7,"title":"Secondary endpoints"},{"claim_count":6,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":8,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":6,"title":"Safety and tolerability"},{"claim_count":1,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":6,"coverage":"discussed","id":"A1","source_count":5,"title":"Treatment positioning and evidence needed to define clinical impact"},{"claim_count":1,"coverage":"discussed","id":"A3","source_count":1,"title":"Sex-subgroup heterogeneity"}],"counts":{"cited_sources":8,"claims_by_expression_type":{"comparison":5,"interpretation":4,"opinion":2,"restatement":1,"uncertainty":1},"claims_by_kind":{"source_observation":13},"clinician_statements":8,"evidence_units":8,"findings":4,"people_cited":7,"people_identity_verified":7,"people_total":7,"screened_sources":21,"verified_claims":13},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":1,"views":4},"has_counterview":false,"limitations":2,"links":{"context":0,"support":11},"ma_question":true,"named_voices":4,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Treatment-changing enthusiasm is explicit, but readiness to define clinical impact varies"},{"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":3,"links":{"context":0,"support":7},"ma_question":true,"named_voices":5,"passages":6,"sources":6,"sources_by_kind":{"commentary":6}},"title":"A favorable overall safety comparison does not remove specific toxicity concerns"},{"id":"F3","structure":{"claims":4,"claims_by_group":{"comparisons":4,"experience":0,"questions":0,"restated":0,"views":0},"has_counterview":false,"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":4,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"The efficacy rationale emphasizes durability against a contemporary comparator"},{"id":"F5","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"has_counterview":false,"limitations":1,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"A sex-subgroup observation remains an unresolved question"}],"medical_affairs_question":"What OS follow-up, biomarker evidence and toxicity characterization would justify moving from these favorable appraisals to routine first-line use in PD-L1-negative advanced nonsquamous NSCLC?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Treatment-changing language meets unresolved evidence maturity"},{"id":"section-2","level":2,"title":"Safety enthusiasm has specific exceptions"},{"id":"section-3","level":2,"title":"Durability, rather than response frequency alone, explains the efficacy enthusiasm"},{"id":"section-4","level":2,"title":"The sex-subgroup signal needs clarification, not a selection rule"},{"id":"section-5","level":2,"title":"Scope, timing and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":4}],"id":"T1","label":"Primary endpoint: Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":4}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":4}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":2}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T08:44:01.797003Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T14:13:25Z","record_hash":"0016c472339fe5953cc55c48c3b57223df7dbf06f29a8e7b8e60fa90525bac72","release_hash":"3fa4693de12ec5d42c0a1146100b07a91ad72744090a867b8895cd1570b00e56","report_id":"erudio-nct06711900","run_id":"bed710ab-21fb-483a-af52-c43d5d90d34d","schema_version":"5.0","slug":"optitrop-lung06-06711900","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"OptiTROP-Lung06 asks whether replacing chemotherapy with sac-TMT alongside pembrolizumab improves outcomes in untreated PD-L1-negative advanced nonsquamous NSCLC. An X poster welcomes the findings but keeps clinical impact conditional. An X poster favors the overall safety comparison while flagging toxicity concerns; response durability anchors an X poster’s efficacy interpretation. Whether these findings justify routine treatment change remains open in an X poster’s appraisal.","meta_description":"21 sources screened · 13 verified statements (8 from clinicians verified by NPI or staff page) from 8 sources · 4 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-ad7733ead9ea043dd41d"],"id":"F1","paraphrase":"Drawing on an X post, this finding asks what would establish readiness for a first-line treatment change.","publication_caveats":{"reason":"Publication-specific caveats are not provided for this source.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-10-25","title":"Treatment-changing enthusiasm is explicit, but readiness to define clinical impact varies"},{"cited_claim_ids":["claim-5180c855914b75cee9cb"],"id":"F2","paraphrase":"Using an X post, this finding asks how overall safety should be considered alongside specific toxicities.","publication_caveats":["The same speaker’s commentary appears in repeated X posts; these do not establish independent endorsements."],"source_channel":"x_thread","source_date":"2026-10-25","title":"A favorable overall safety comparison does not remove specific toxicity concerns"}]},"publication":{"approved_at":"2026-10-29T14:13:25Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":21},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","1 matching source (1 X thread) could not be read and is not included.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits apply, so some matching discussion may be missing.","The report describes short-form commentary, not an assessment of the complete trial data. Results publications used as trial context are separate from the commentary synthesis. No protocol is listed in the available registry information, and regulatory information is incomplete.","Some potentially relevant sources and passages were not fully assessed, including discussions without an explicit trial name; one additional source could not be read. Additional views or qualifications may be missing.","Eight posts do not represent eight independent HCP views: two repeat a speaker’s commentary, and reposts are not separate endorsements.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The immature, exploratory OS analysis, limited toxicity detail and unquantified sex-subgroup observation constrain conclusions about adoption and patient selection."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":7,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":8},"count":8,"evidence_window":{"end":"2026-10-25","start":"2026-09-23"},"retrieval_snapshot":"2026-10-29T08:08:17.723517Z","timeline":[{"count":1,"week":"2026-W39"},{"count":7,"week":"2026-W43"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06711900:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06711900:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:42929694","quote_policy":"short_quote_link_out"},{"id":"openfda:097d166f-b73b-41d3-9b37-7653cd2a0c41:20260731","quote_policy":"short_quote_link_out"},{"id":"openfda:caef07ce-066b-4c48-98dc-974b05ebbbe0:20260618","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mqozz5m6g22a","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3myx2i4djyk2l","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hslirr7h6d7livppaxty435b-3myozfgl22g2v","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mgwrki6irihfcatu2v347soc-3myouvxjwwq2m","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-xhrtfphu4gzqrztkpb3a63qf-3mqntker2i424","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-yk5mvwzdjpy45i4ph7at4xmx-3myp4adrtq22w","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7508546383923228673","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2077850795127509424:63d5f6eb-2614-4adf-9415-0ec505227441","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2102759897570099204:242b38ef-a395-482e-beba-a630fd637d13","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114195560810922003:e936d77d-222b-4207-a2b7-f6524872e0aa","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114206067345522754:258d2d46-6d94-44e1-8ec0-081e48988124","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114297041790857238:5861b0b1-d6d3-4e89-bd70-fe0c6de9515d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114297097344188804:bd922ece-94e7-494c-b79c-78aa937f105f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114297334024556760:cae44b3d-3108-4b68-9ea0-c717dbe778ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114297558088679848:1843e7d3-4fd6-49f9-aaf1-a19112014cb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114297760979566987:69279803-ed0e-440d-8026-35158010318d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114297880114774087:d2ba0db1-14fe-4051-9820-a069ba641e69","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114298720711811565:09810c8b-494e-421d-acc1-2655db1c661b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114299099398713405:21e3d4e1-3356-4569-b13a-f3320999b9e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114301068947382617:bf5b7176-68b1-46ea-ab10-fd2641e4b080","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114303578882121975:a7ec65c5-ac95-46a3-8f22-4ab8c58e350e","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":6,"linkedin_post":1,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":14,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":21},"count":21,"evidence_window":{"end":"2026-10-28","start":"2026-07-15"},"retrieval_snapshot":"2026-10-29T08:08:17.956927Z","timeline":[{"count":3,"week":"2026-W29"},{"count":2,"week":"2026-W39"},{"count":15,"week":"2026-W43"},{"count":1,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: skb264","status":"unmapped"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"},{"reason":"Unmapped registry intervention: carboplatin or cisplatin","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"OptiTROP-Lung06","aliases":["OptiTROP-Lung06","SKB264-Ⅲ-14","A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer"],"brief_title":"A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":432,"type":"ESTIMATED"},"interventions":[{"name":"SKB264","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"carboplatin or cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06711900","official_title":"A Randomized, Open-Label, Multicenter Phase 3 Clinical Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-12","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first.","measure":"Progression Free Survival (PFS) assessed by Blinded Independent Central Review (BICR)","timeFrame":"Randomization up to approximately 28 months"}],"registered_date":{"date":"2024-12-02","type":"ACTUAL"},"registry_last_updated":"2026-07-08","registry_url":"https://clinicaltrials.gov/study/NCT06711900","short_name":"OptiTROP-Lung06","short_name_basis":"canonical_name","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","start_date":{"date":"2024-10-30","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"SKB264-Ⅲ-14","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}